Description: Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
Home Page: www.contineum-tx.com
10578 Science Center Drive
San Diego,
CA
92121
United States
Phone:
858 333 5280
Officers
| Name | Title |
|---|---|
| Mr. Carmine N. Stengone MBA, MS | President, CEO, Secretary & Director |
| Mr. Peter T. Slover CPA | Chief Financial Officer |
| Dr. Daniel S. Lorrain Ph.D. | Chief Science Officer |
| Morgan Paulsen | Senior Manager of Accounting |
| Mr. John Healy | General Counsel & Corporate Secretary |
| Dr. Stephen L. Huhn F.A.A.P, F.A.C.S., M.D. | Chief Medical Officer & Senior VP of Clinical Development |
| Mr. Austin Chen Ph.D. | Senior VP & Head of Research |
| Mr. Michael Mayberry | Senior Director & Corporate Controller |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.2672 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2024-04-05 |
| Fiscal Year End: | December |
| Full Time Employees: | 31 |